| abstract |
[MEANS FOR SOLVING PROBLEMS] As a result of intensive studies on EP4 receptor agonists, the inventors have found that the 1-position of the pyridone ring is substituted with a group having an acidic group such as a carboxyl group, and the 6-position is a lower alkyl, lower alkylene, ether or thioether. It was confirmed that a novel pyridone compound characterized by being bonded to an aromatic ring group via a has a good EP4 receptor agonistic action, and the present invention was completed. Since the compound of the present invention has a good EP4 receptor agonistic action and a rat hindlimb blood flow increasing action, it is useful as a pharmaceutical, particularly a therapeutic agent for peripheral arterial occlusion. [Selection figure] None |